Holen Sie sich die Stockscreener-App
1.02
7.27%
-0.08
Vorhandelsmarkt:
1.05
0.03
+2.94%
Schlusskurs vom Vortag:
$1.10
Offen:
$1.08
24-Stunden-Volumen:
159.10K
Relative Volume:
0.05
Marktkapitalisierung:
$7.90M
Einnahmen:
$34.07M
Nettoeinkommen (Verlust:
$-20.13M
KGV:
-0.0789
EPS:
-12.92
Netto-Cashflow:
$-24.90M
1W Leistung:
-2.86%
1M Leistung:
+4.24%
6M Leistung:
+0.99%
1J Leistung:
-37.80%
1-Tages-Spanne:
$1.01
$1.10
1-Wochen-Bereich:
$0.9701
$1.11
52-Wochen-Spanne:
$0.61
$2.4302
Biofrontera Inc Stock (BFRI) Company Profile
Firmenname
Biofrontera Inc
Sektor
Telefon
781-245-1325
Adresse
120 PRESIDENTIAL WAY,, WOBURN
Vergleichen Sie BFRI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
1.02 | 7.90M | 34.07M | -20.13M | -24.90M | -12.92 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Biofrontera Inc Aktie (BFRI) Neueste Nachrichten
Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study - TipRanks
Biofrontera Inc. Announces Achievement of Key Milestone In - GlobeNewswire
Biofrontera's Ameluz-PDT Skin Cancer Treatment Hits All Phase 3 Endpoints with Strong Results - StockTitan
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - The Manila Times
Biofrontera Hits Major Milestone: 100th RhodoLED® XL Lamp Installed as PDT Treatment Demand Surges - StockTitan
Opendoor Technologies Inc (OPEN-Q) QuotePress Release - The Globe and Mail
Financial Contrast: Biofrontera (NASDAQ:BFRI) versus Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Biofrontera Inc (BFRI:UR): Stock Price, Quote and News - BNN Bloomberg
Biofrontera to Present at Benchmark's Discovery Investor Conference in NYC - StockTitan
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Yahoo Finance
Biofrontera Inc. announced that it expects to receive $4.2 million in funding - Marketscreener.com
Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewswire
Biofrontera Secures $4.2M for Strategic Growth Initiatives - TipRanks
Biofrontera Secures $4.2M Financing Through Convertible Note Deal with Key Shareholders | BFRI Stock News - StockTitan
Biofrontera AG announced that it has received $4.2 million in funding - Marketscreener.com
Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Earnings call: Biofrontera reports modest revenue growth in Q3 2024 - Investing.com
Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey
Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com
Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire
Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan
Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com
Ameluz photodynamic therapy yields positive results in first US phase 3 study for sBCC - Healio
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance
Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia
Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance
Biofrontera Announces Promising Phase 3 Study Results - TipRanks
Biofrontera reports breakthrough in skin cancer treatment - Investing.com
Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire
Actinic Keratosis Treatment Market Expected to Reach Huge - openPR
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance
Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia
Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India
Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan
BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Mass. Biotech Receives FDA Approval - Streetwise Reports
Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa
Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India
What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News
Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks
Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks
Finanzdaten der Biofrontera Inc-Aktie (BFRI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):